An interventional study of Implantable Loop Recorder in Fabry Disease, sponsored by University Hospital Birmingham NHS Foundation Trust. Active, not recruiting at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-14.
Sponsored by University Hospital Birmingham NHS Foundation Trust · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Fabry Disease with a site in United Kingdom — 7 open to participants now, 13 under way, 6 of them phase 3. Fabry Disease · United Kingdom.
Among the 52 studies in Fabry Disease with a site in United Kingdom, this one has the largest enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2019, is the only one with no phase, reaches primary completion later than 3 of the 12 other live ones, and was the 28th registered.
244 studies on the registry are indexed under Fabry Disease; 55 are open to participants now.
Browse Fabry Disease studies →7 of the 52 studies in Fabry Disease with a site in United Kingdom are open now. Recruiting first, the newest first:
Idorsia Pharmaceuticals Ltd. · Sites in United Kingdom, United States, Canada and 2 more countries
Ages 18–60 · Men only
Amicus Therapeutics · Sites in United Kingdom, United States, Belgium and 3 more countries
Ages 2–11
Chiesi Farmaceutici S.p.A. · Sites in United Kingdom, United States, Austria and 3 more countries
Ages 2–17
Chiesi Farmaceutici S.p.A. · Sites in United Kingdom, United States, Germany and 2 more countries
Women only
Chiesi Farmaceutici S.p.A. · Sites in United Kingdom, United States, Slovenia
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 45 Fabry Disease studies recruiting now, 32 (71%) set no upper age limit and 11 (24%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 23 · Phase 4 3
First in 1999; this study’s year is marked. 5 started in 2019.
This study's enrollment of 169 is above the median of 22 across 108 interventional studies indexed under Fabry Disease.
Median enrollment 30 across the 39 interventional studies, 100 across the 13 observational. Of the 38 that completed or were terminated, 28 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 52 have an industry lead sponsor. The 10 most frequent:
University Hospital Birmingham NHS Foundation Trust is the lead sponsor of 36 studies on the registry; 1 is open to participants now.
University Hospital Birmingham NHS Foundation Trust has 1 study filed under Fabry Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Fabry Disease with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 52 studies in Fabry Disease with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Fabry disease (FD) is a genetic disorder that leads to progressive accumulation of fat or 'sphingolipid' within the tissues, including the heart muscle and conductive tissue. Improvements in the detection of FD, together with more organised clinical services for rare diseases, has led to a rapid growth in the disease prevalence. Earlier and more frequent diagnosis of asymptomatic individuals before development of the disease itself has focused attention on early detection of organ involvement and closer monitoring of disease progression. Moreover, the introduction of enzyme replacement therapy within the last two decades has changed the natural history of FD as follows: a) increased life expectancy; b) improved morbidity; c) modification of the main cause of morbidity and mortality from renal (kidney) to cardiovascular (heart) events, including heart failure, abnormal heart rhythms, stroke and sudden death. Although symptoms such as palpitations and blackouts are extremely common, information on the frequency of proven abnormal heart rhythms is limited. In addition, the rate and appropriateness of implantation of life-saving devices is very variable, including pacemakers to boost the heart when too slow and cardio-defibrillators that stop the heart when too fast. The main markers of risk in similar diseases such as hypertrophic cardiomyopathy cannot be used in FD. While patients are routinely followed up in clinic with heart tracings and echocardiography (ultrasound of the heart), a recent small study has emphasised that these tests under-estimate the burden of abnormal heart rhythms in patients with advanced FD. The use of continuous heart monitoring with an implantable loop recorder (ILR) has led to a significant change in treatment in 13 out of 15 of FD patients. The investigators believe that more frequent use of ILRs will identify a greater need for change in therapy in many more patients than currently treated, with the aim of reducing morbidity and mortality in this patient cohort. In addition this will provide valuable data to inform an estimate of future risk for these patients.
This is a 3-year open-label multicentre randomised controlled trial assessing arrhythmia burden in patients with Fabry cardiac disease. This is an observational study, but with implantable loop recorder (ILR) insertion at recruitment and removal at end of trial for the intervention arm.
Null hypothesis: There will be no difference in the identification of arrhythmia between patients following standard care compared to patients following standard care but with the addition of ILR monitoring.
Beyond the proposed hypothesis, data collected will be used to inform whether ILR in FD will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Using an Implantable Loop Recorder fo continuous rhythm monitoring and home follow-up. This will be combined with standard care procedure, which will include annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
Device: Implantable Loop Recorder
The standard of care with annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
An implantable loop recorder (ILR), also known as an insertable cardiac monitor, is a small device (smaller than a AAA battery) that is inserted under the skin on the front of the chest. The ILR is inserted using local anesthetic as an out-patient procedure and lasts approximately 30 minutes. The ILR captures a continuous ECG of your heart activity, which allows doctors to detect any abnormal heart rhythms at any point. If you have the ILR, you will have the device for 3 years, after which it will be removed under local anesthetic during an out-patient procedure, again lasting approximately 30 minutes. The ILR device is completely safe and shouldn't affect your day to day living.
First occurrence of atrial fibrillation (AF) requiring anticoagulation
This will include all descriptions of AF, which can be defined as: 1. paroxysmal - self-terminating episodes lasting between 48 hours to 7 days 2. persistent - intermittent episodes lasting between 7 days to 1 year 3. permanent - episodes lasting longer than 1 year
Time frame: Total monitoring time period in study - 3 years
First occurrence of bradyarrhythmia requiring cardiac pacing
This would include: 1. Symptomatic significant AV block. 2. Mobitz type 2 AV block or complete heart block irrespective of symptoms.
Time frame: Total monitoring time period in study - 3 years
First occurrence of supraventricular arrhythmia requiring drug treatment or ablation.
Time frame: Total monitoring time period in study - 3 years
First occurrence of non-sustained ventricular tachyarrhythmia requiring drug treatment, ICD implantation or ablation
This is classified as three or more ventricular beats at a rate \>120bpm, for a duration of less than 30 seconds.
Time frame: Total monitoring time period in study - 3 years
Frequency of arrhythmia in patients with and without late gadolinium enhancement (LGE)
The study will aim at quantifying the extent of LGE deposited with myocardial tissue on cardiac MRI scanning. This will subsequently be correlated with the burden of arrhythmia detected to assess for potential risk factors.
Time frame: 3 years
Frequency of arrhythmia according to location of myocardial fibrosis (inferolateral vs. non-inferolateral)
The study will aim to correlate the location of myocardial fibrosis with the presence or absence of cardiac arrhythmia to define location of fibrosis as a potential risk factor for arrhythmia.
Time frame: 3 years
Frequency of arrhythmia in those patients with a QRS duration greater or less than 120ms
Time frame: 3 years
Frequency of arrhythmia in those with an atrial size above or below indexed normal range for age and sex
Time frame: 3 years
Plan to share: No — There is no plan to make individual participant data available to other researchers. Data analysis conducted using anonymised patient data will be shared through publications.
Started Sep 2019 (actual). Primary completion is estimated for Jul 2026, 82 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Birmingham NHS Foundation Trust